David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.31% |
| 2 | Healthcare | 10.66% |
| 3 | Consumer Discretionary | 10.29% |
| 4 | Communication Services | 8.78% |
| 5 | Financials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
REV
2851
CALL
DELISTED
Revlon, Inc.
REV
| $520K | ﹤0.01% |
21,200
+200
| +1% | +$3.87K |
|
2852
Home BancShares
HOMB
$6.01B
| $519K | ﹤0.01% |
20,562
-95,146
| -82% | -$2.29M |
|
2853
Nektar Therapeutics
NKTR
$2.52B
| $519K | ﹤0.01% |
1,443
-7,610
| -84% | -$2.38M |
|
|
DRD
2854
DRDGold
DRD
$2.68B
| $518K | ﹤0.01% |
134,600
-112,049
| -45% | -$378K |
|
2855
CALL
Advanced Energy
AEIS
$11B
| $517K | ﹤0.01% |
6,400
| – | – |
|
2856
Supernus Pharmaceuticals
SUPN
$2.62B
| $514K | ﹤0.01% |
12,852
-4,396
| -25% | -$190K |
|
|
SIOX
2857
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $513K | ﹤0.01% |
9,324
-201,593
| -96% | -$34M |
|
|
FBR
2858
DELISTED
Fibria Celulose Sa
FBR
| $513K | ﹤0.01% |
+37,885
| New | +$450K |
|
2859
Designer Brands
DBI
$297M
| $512K | ﹤0.01% |
23,826
+84
| +0.4% | +$1.54K |
|
2860
TTEC Holdings
TTEC
$67M
| $512K | ﹤0.01% |
12,253
-9,393
| -43% | -$380K |
|
|
CBF
2861
DELISTED
Capital Bank Financial Corp. Class A Common Stock
CBF
| $511K | ﹤0.01% |
12,453
+3,835
| +44% | +$146K |
|
2862
Novavax
NVAX
$1.46B
| $509K | ﹤0.01% |
22,305
-253,177
| -92% | -$5.67M |
|
2863
Compass Minerals
CMP
$1.03B
| $505K | ﹤0.01% |
7,785
-14,789
| -66% | -$988K |
|
2864
Nutanix
NTNX
$18B
| $505K | ﹤0.01% |
22,553
+11,024
| +96% | +$241K |
|
|
GFN
2865
DELISTED
General Finance Corporation
GFN
| $505K | ﹤0.01% |
100,000
| – | – |
|
2866
Dime Commercial Bancshares
DCOM
$1.78B
| $504K | ﹤0.01% |
14,841
-553
| -4% | -$17.7K |
|
|
PFSW
2867
DELISTED
PFSweb, Inc.
PFSW
| $503K | ﹤0.01% |
60,240
+12,639
| +27% | +$100K |
|
|
SSI
2868
DELISTED
Stage Stores Inc
SSI
| $501K | ﹤0.01% |
272,310
+129,327
| +90% | +$239K |
|
2869
REX American Resources
REX
$1.4B
| $500K | ﹤0.01% |
31,944
-3,900
| -11% | -$61.2K |
|
|
MDSO
2870
PUT
DELISTED
Medidata Solutions, Inc.
MDSO
| $500K | ﹤0.01% |
6,400
| – | – |
|
2871
Build-A-Bear
BBW
$487M
| $499K | ﹤0.01% |
54,590
+35,338
| +184% | +$333K |
|
2872
CALL
Constellation Brands
STZ
$23.5B
| $499K | ﹤0.01% |
2,500
| – | – |
|
2873
PUT
Travere Therapeutics
TVTX
$6.15B
| $498K | ﹤0.01% |
20,000
| – | – |
|
2874
CALL
Century Aluminum
CENX
$4.32B
| $497K | ﹤0.01% |
30,000
| – | – |
|
2875
Tejon Ranch
TRC
$440M
| $497K | ﹤0.01% |
24,238
-7,338
| -23% | -$147K |
|
Similar funds
David Shaw's Q3 2017 Portfolio in Review
As of Q3 2017, David Shaw held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
David Shaw's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- David Shaw's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- David Shaw added most to Comcast in Q3 2017, an estimated $354M increase.
- David Shaw's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- David Shaw fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- David Shaw's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- David Shaw opened 469 new positions and closed 370 in Q3 2017.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.